Study overview. First, genome data from TCGA, publicly available PDX models, and an additional cohort were collected. Second, immunoediting scores calculated by four types of methods (including five specific methods) are compared to assess the consistency of these methods in measuring immunoediting scores and the ability to detect immunoediting events in tumors. Finally, the potential impact of neoantigen selection strategies, mutation counts, HLA alleles, clinical features, and reference datasets on the performance of these methods is assessed.
